Skip to main content
Telo Genomics Corp. logo

Telo Genomics Corp. — Investor Relations & Filings

Ticker · TELO TSXV Professional, scientific and technical activities
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-02-26 Regulatory Filings
Country CA Canada
Listing TSXV TELO

About Telo Genomics Corp.

https://www.telodx.com/

Telo Genomics Corp. is a molecular diagnostics company specializing in developing predictive and prognostic solutions utilizing its proprietary telomere-based platform. The core technology, TeloView®, quantifies genomic instability by measuring the 3D structure and spatial organization of telomeres. This platform is designed to provide actionable information regarding disease aggressiveness and potential response to treatment, helping to tailor therapeutic approaches. Applications focus primarily on multiple cancers (oncology) and neurodegenerative diseases (CNS). The company is pioneering the most comprehensive telomere platform in the industry to address unmet market needs.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate—a regulatory certification by the CEO confirming review and fair presentation of the interim financial report and MD&A for the period ended December 31, 2024. It is not the interim report itself (IR), nor an audit report (AR), earnings release, or other specific category. It does not announce publication or link to a report. It is a mandatory regulatory filing certificate that doesn’t fit other specific categories, so it falls into the general Regulatory Filings (RNS) category.
2025-02-26 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is a standalone Management’s Discussion and Analysis (MD&A) for the three and six months ended December 31, 2024 and 2023, prepared under Canadian NI 51-102 continuous disclosure rules. It focuses on management’s analysis of operations, forward-looking statements, risks, business overview and patents, without including full financial statements or earnings highlights only. This aligns precisely with our “Management Reports (MDA)” category.
2025-02-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for Telo Genomics Corp. for the three and six months ended December 31, 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2025
2025-02-26 English
Report of exempt distribution (45-106F1).pdf
Capital/Financing Update Classification · 1% confidence The document is titled “Form 45-106F1 Report of Exempt Distribution,” a mandatory Canadian securities regulator filing under NI 45-106 detailing a private placement (units and warrants), purchaser allocations and compensation. This is a detailed disclosure of a financing transaction (exempt distribution of securities) rather than an earnings release, management report or proxy statement. It best matches the “Capital/Financing Update” category, which covers updates on company fundraising and financing activities.
2025-01-03 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Form 51-102F3 “Material Change Report” under Canadian securities rules announcing the closing of an over-subscribed $2.5 million non-brokered private placement of units (common shares plus warrants), detailing the offering terms, use of proceeds, finder’s fees, related party participation, hold periods, and exchange acceptance. This is a fundraising transaction and capital structure update, matching the “Capital/Financing Update” category rather than a full annual/interim report or simple regulatory notice. Hence, it is classified as CAP.
2024-12-24 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a $2.5 million private placement, detailing the number of units issued, warrants, use of proceeds, and related party participation. It is a financing activity update rather than a full report, making it a Capital/Financing Update.
2024-12-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.